Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Other Accumulated Expenses: 2021-2022

Historic Other Accumulated Expenses for Amylyx Pharmaceuticals (AMLX) over the last 2 years, with Dec 2022 value amounting to $1.0 million.

  • Amylyx Pharmaceuticals' Other Accumulated Expenses rose 289.53% to $1.0 million in Q4 2022 from the same period last year, while for Dec 2022 it was $1.0 million, marking a year-over-year increase of 289.53%. This contributed to the annual value of $1.0 million for FY2022, which is 289.53% up from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported Other Accumulated Expenses of $1.0 million as of FY2022, which was up 289.53% from $258,000 recorded in FY2021.
  • In the past 5 years, Amylyx Pharmaceuticals' Other Accumulated Expenses registered a high of $1.0 million during FY2022, and its lowest value of $258,000 during FY2021.
  • Moreover, its 2-year median value for Other Accumulated Expenses was $631,500 (2021), whereas its average is $631,500.
  • Data for Amylyx Pharmaceuticals' Other Accumulated Expenses shows a peak YoY surged of 289.53% (in 2022) over the last 5 years.
  • Amylyx Pharmaceuticals' Other Accumulated Expenses (Yearly) stood at $258,000 in 2021, then skyrocketed by 289.53% to $1.0 million in 2022.